• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ERJ Open Res . Outcomes of COVID-19 patients treated with continuous positive airway pressure outside the intensive care unit

tetano

Editor, Senior Moderator
ERJ Open Res


. 2021 Jan 25;7(1):00541-2020.
doi: 10.1183/23120541.00541-2020. eCollection 2021 Jan.
Outcomes of COVID-19 patients treated with continuous positive airway pressure outside the intensive care unit


Rosanna Vaschetto[SUP] 1 2 3 [/SUP], Francesco Barone-Adesi[SUP] 2 3 [/SUP], Fabrizio Racca[SUP] 4 [/SUP], Claudio Pissaia[SUP] 5 [/SUP], Carlo Maestrone[SUP] 6 [/SUP], Davide Colombo[SUP] 7 [/SUP], Carlo Olivieri[SUP] 8 [/SUP], Nello De Vita[SUP] 2 [/SUP], Erminio Santangelo[SUP] 2 [/SUP], Lorenza Scotti[SUP] 2 [/SUP], Luigi Castello[SUP] 2 9 [/SUP], Tiziana Cena[SUP] 1 [/SUP], Martina Taverna[SUP] 4 [/SUP], Luca Grillenzoni[SUP] 10 [/SUP], Maria Adele Moschella[SUP] 11 [/SUP], Gianluca Airoldi[SUP] 12 [/SUP], Silvio Borr?[SUP] 13 [/SUP], Francesco Mojoli[SUP] 14 [/SUP], Francesco Della Corte[SUP] 1 2 [/SUP], Marta Baggiani[SUP] 2 [/SUP], Sara Baino[SUP] 2 [/SUP], Piero Balbo[SUP] 15 [/SUP], Simona Bazzano[SUP] 1 [/SUP], Valeria Bonato[SUP] 4 [/SUP], Sara Carbonati[SUP] 2 [/SUP], Federico Crimaldi[SUP] 2 [/SUP], Veronica Daffara[SUP] 2 [/SUP], Luca De Col[SUP] 5 [/SUP], Matteo Maestrone[SUP] 2 [/SUP], Mario Malerba[SUP] 2 16 [/SUP], Federica Moroni[SUP] 2 [/SUP], Raffaella Perucca[SUP] 1 [/SUP], Mario Pirisi[SUP] 2 17 [/SUP], Valentina Rondi[SUP] 2 [/SUP], Daniela Rosalba[SUP] 2 [/SUP], Letizia Vanni[SUP] 2 [/SUP], Francesca Vigone[SUP] 2 [/SUP], Paolo Navalesi[SUP] 18 3 [/SUP], Gianmaria Cammarota[SUP] 1 3 [/SUP]



Affiliations

Abstract

Aim: We aimed to characterise a large population of coronavirus disease 2019 (COVID-19) patients with moderate-to-severe hypoxaemic acute respiratory failure (ARF) receiving continuous positive airway pressure (CPAP) outside the intensive care unit (ICU), and to ascertain whether the duration of CPAP application increased the risk of mortality for patients requiring intubation.
Methods: In this retrospective, multicentre cohort study, we included adult COVID-19 patients, treated with CPAP outside ICU for hypoxaemic ARF from 1 March to 15 April, 2020. We collected demographic and clinical data, including CPAP therapeutic goal, hospital length of stay and 60-day in-hospital mortality.
Results: The study included 537 patients with a median (interquartile range (IQR) age of 69 (60-76) years. 391 (73%) were male. According to the pre-defined CPAP therapeutic goal, 397 (74%) patients were included in the full treatment subgroup, and 140 (26%) in the do not intubate (DNI) subgroup. Median (IQR) CPAP duration was 4 (1-8) days, while hospital length of stay was 16 (9-27) days. 60-day in-hospital mortality was 34% (95% CI 0.304-0.384%) overall, and 21% (95% CI 0.169-0.249%) and 73% (95% CI 0.648-0.787%) for full treatment and DNI subgroups, respectively. In the full treatment subgroup, in-hospital mortality was 42% (95% CI 0.345-0.488%) for 180 (45%) CPAP failures requiring intubation, and 2% (95% CI 0.008-0.035%) for the remaining 217 (55%) patients who succeeded. Delaying intubation was associated with increased mortality (hazard ratio 1.093, 95% CI 1.010-1.184).
Conclusions: We described a large population of COVID-19 patients treated with CPAP outside ICU. Intubation delay represents a risk factor for mortality. Further investigation is needed for early identification of CPAP failures.
 
Back
Top Bottom